Barbara Lettieroaffiliated with the university, Postdoc


Research areas and keywords

UKÄ subject classification

  • Cancer and Oncology


  • Statins; breast cancer progression; lipid metabolism; molecular biomarkers


Epidemiological evidence highlighted the remarkable beneficial role of cholesterol lowering medicines-in particular statins- in reducing the risk of breast cancer (BC) recurrence. Despite the significant antitumor effects on BC cells and primary tumors heterogeneity of responses to statin therapy is a noteworthy issue that needs to be addressed before statin introduction in clinical settings. Recently, we proposed that defects in the regulation of genes involved in cholesterol biosynthesis may likely predict responsiveness to statin treatment. Hence, our current research goal is to thoroughly evaluate whether these antitumor effects of statins can be associated to a more general alteration in the level and in the regulation- uptake, storage and synthesis- of intracellular lipids in BC cells. This would help in better characterizing the molecular and biological mechanisms that can discriminate between statin sensitive and insensitive BC cells. It will in turn help in better identifying which BC patients will most likely benefit from statin therapy. 

Recent research outputs

View All (4)